Skip to main content
NVDA+0.53%AAPL+0.02%GOOGL-0.61%MSFT+0.30%AMZN+0.37%TSM+0.96%SPCX+5.15%META+0.33%AVGO+0.07%TSLA+0.32%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.61%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%ORCL+2.00%BAC-2.72%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%3988.HK+0.34%GE+1.91%1816.HK-0.69%MS-1.83%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%USDJPY+1.74%NZDUSD-1.63%AUDUSD-1.18%USDCHF+1.14%EURUSD-1.13%GBPUSD-1.07%USDTHB+1.06%CADJPY+0.92%USDCAD+0.84%NZDCAD-0.81%CHFJPY+0.71%GBPJPY+0.63%EURJPY+0.57%GBPNZD+0.57%AUDJPY+0.56%NZDCHF-0.50%EURNZD+0.50%AUDNZD+0.46%GBPTRY+0.41%EURCAD-0.34%AUDCAD-0.34%USDTRY+0.33%GBPHKD+0.32%CADCHF+0.30%GBPMXN-0.28%GBPCAD-0.25%USDILS+0.16%NZDMXN+0.11%NZDJPY+0.11%GBPAUD+0.09%NZDSGD+0.08%USDCNH+0.07%USDZAR+0.06%EURAUD+0.05%AUDSGD-0.05%USDCOP-0.04%GBPCHF+0.04%EURGBP-0.04%AUDCHF-0.03%GBPSGD-0.03%USDSGD-0.03%USDHKD+0.02%USDMXN+0.01%EURCHF+0.01%SGDJPY+0.01%EURSGD-0.01%CHFSGD0.00%EURSEK0.00%GBPZAR0.00%PLNJPY0.00%USDSEK0.00%EURNOK0.00%EURDKK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%NOKJPY0.00%USDPLN0.00%EURCZK0.00%CHFNOK0.00%USDNOK0.00%USDDKK0.00%EURPLN0.00%XPTUSD+0.64%USOIL-0.30%XNGUSD+0.27%XAUUSD+0.24%GAUUSD+0.24%XAGUSD+0.13%GAGUSD+0.13%HG1+0.09%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.11%ETHUSD-0.15%USDTUSD+0.01%XRPUSD+0.22%SOLUSD+0.78%TRXUSDT+0.79%ZECUSDT+17.82%DOGEUSD+0.11%XMRUSDT-3.32%LINKUSD-0.04%XLMUSD+1.89%BCHUSDT+0.59%UNIUSD+0.48%LTCUSD-0.65%TONUSD+29.54%HBARUSDT-2.01%SUIUSD+2.12%TAOUSDT+0.51%AAVEUSD-2.61%DOTUSDT+6.14%ICPUSDT+1.32%ONDOUSDT+2.74%WLDUSDT+1.27%ARBUSDT+7.44%ATOMUSDT-1.81%JUPUSDT-1.19%INJUSDT-1.26%STXUSDT+1.58%FETUSDT+2.27%PYTHUSDT-1.57%TIAUSDT+2.39%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.65%OPUSDT-0.14%WIFUSDT+1.40%POLUSDT+1.09%IOTAUSDT-0.79%AXSUSDT+0.03%FARTCOINUSDT-1.32%EOSUSDT-0.84%DYDXUSDT-0.39%ORDIUSDT+2.65%GALAUSDT-2.76%NOTUSDT+1.37%RONINUSDT-2.40%NVDA+0.53%AAPL+0.02%GOOGL-0.61%MSFT+0.30%AMZN+0.37%TSM+0.96%SPCX+5.15%META+0.33%AVGO+0.07%TSLA+0.32%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.61%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%ORCL+2.00%BAC-2.72%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%3988.HK+0.34%GE+1.91%1816.HK-0.69%MS-1.83%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%USDJPY+1.74%NZDUSD-1.63%AUDUSD-1.18%USDCHF+1.14%EURUSD-1.13%GBPUSD-1.07%USDTHB+1.06%CADJPY+0.92%USDCAD+0.84%NZDCAD-0.81%CHFJPY+0.71%GBPJPY+0.63%EURJPY+0.57%GBPNZD+0.57%AUDJPY+0.56%NZDCHF-0.50%EURNZD+0.50%AUDNZD+0.46%GBPTRY+0.41%EURCAD-0.34%AUDCAD-0.34%USDTRY+0.33%GBPHKD+0.32%CADCHF+0.30%GBPMXN-0.28%GBPCAD-0.25%USDILS+0.16%NZDMXN+0.11%NZDJPY+0.11%GBPAUD+0.09%NZDSGD+0.08%USDCNH+0.07%USDZAR+0.06%EURAUD+0.05%AUDSGD-0.05%USDCOP-0.04%GBPCHF+0.04%EURGBP-0.04%AUDCHF-0.03%GBPSGD-0.03%USDSGD-0.03%USDHKD+0.02%USDMXN+0.01%EURCHF+0.01%SGDJPY+0.01%EURSGD-0.01%CHFSGD0.00%EURSEK0.00%GBPZAR0.00%PLNJPY0.00%USDSEK0.00%EURNOK0.00%EURDKK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%NOKJPY0.00%USDPLN0.00%EURCZK0.00%CHFNOK0.00%USDNOK0.00%USDDKK0.00%EURPLN0.00%XPTUSD+0.64%USOIL-0.30%XNGUSD+0.27%XAUUSD+0.24%GAUUSD+0.24%XAGUSD+0.13%GAGUSD+0.13%HG1+0.09%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.11%ETHUSD-0.15%USDTUSD+0.01%XRPUSD+0.22%SOLUSD+0.78%TRXUSDT+0.79%ZECUSDT+17.82%DOGEUSD+0.11%XMRUSDT-3.32%LINKUSD-0.04%XLMUSD+1.89%BCHUSDT+0.59%UNIUSD+0.48%LTCUSD-0.65%TONUSD+29.54%HBARUSDT-2.01%SUIUSD+2.12%TAOUSDT+0.51%AAVEUSD-2.61%DOTUSDT+6.14%ICPUSDT+1.32%ONDOUSDT+2.74%WLDUSDT+1.27%ARBUSDT+7.44%ATOMUSDT-1.81%JUPUSDT-1.19%INJUSDT-1.26%STXUSDT+1.58%FETUSDT+2.27%PYTHUSDT-1.57%TIAUSDT+2.39%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.65%OPUSDT-0.14%WIFUSDT+1.40%POLUSDT+1.09%IOTAUSDT-0.79%AXSUSDT+0.03%FARTCOINUSDT-1.32%EOSUSDT-0.84%DYDXUSDT-0.39%ORDIUSDT+2.65%GALAUSDT-2.76%NOTUSDT+1.37%RONINUSDT-2.40%
PT

Palvella Therapeutics, Inc. (PVLA)

NASDAQ • Healthcare

$151.43
+$0.21 (+0.1%)
Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$152.54
Day Range$150.76 - $155.08
Avg. Volume (3M)197.5K
Market Cap$2.1B
52 Week Range
$54.48$161.38
Next EarningsIn 55 daysNov 10, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$61.6M
EPS (TTM)
-$4.83
ROA (TTM)
-24.34%
Current Ratio
21.18

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-18.5%Q1 2026-$1.08
-33.3%Q2 2026-$1.2
-29.9%Q3 2026-$1.52
Next

Nov 10

in 55 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -29.9%

Palvella Therapeutics’ preliminary results showed EPS trailing consensus in the second fiscal quarter of 2026, reported August 4, 2026, with EPS of -$1.52 trailing the -$1.17 estimate by -$0.35. The clinical-stage biotech, focused on inherited skin conditions including its QTORIN rapamycin gel program, posted a GAAP net loss of about $21.9 million, deeper than the roughly $9.5 million loss a year ago (net income YoY -130.9%), while operating income was about -$21.4 million. EPS was down -76.7% year over year from -$0.86. Cash generation was also negative, with operating cash flow of about -$12.8 million. For the next period, consensus calls for EPS of -$1.74 on revenue of $16,667.00.

View full earnings history

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops treatments for inherited skin conditions. In qualitative terms, it is a clinical-stage biopharmaceutical company, with its work centered on QTORIN 3.9% rapamycin anhydrous gel and related rapamycin programs rather than commercialized product sales.

Name
Palvella Therapeutics, Inc.
CEO
Wesley H. Kaupinen
Website
palvellatx.com
Industry
Healthcare
Employees
29

Today's Snapshot

AI-generated

PVLA closed slightly higher at 151.43, in line with a flat sector.

Trading Volume

Above 10d avg 192.0K

199.7K

vs S&P 500 Today

Outperforming Market

+0.72%

Updated: September 16, 2026 at 20:21 UTC

Technical Indicators

4 Buy3 Neutral1 Sell
PVLA has a generally constructive technical profile, with the current price above several medium- and long-term moving averages and modest positive momentum as reflected in the MACD and small positive momentum reading. ADX is low, suggesting the advance lacks strong trend force, and volatility is moderate while on-balance volume shows net outflow, tempering enthusiasm. The market trades near the pivot area, indicating equilibrium between buyers and sellers at current levels. Technical takeaway: Buy — price sits above key medium- and long-term averages with mild positive momentum but weak trend conviction.
All signals
  • EMA (5 indicators)$120.76 - $151.55
    Buy
  • RSI (14)51.60
    Neutral
  • Stochastic %K (14, 3, 3)55.16
    Neutral
  • MACD Level (12, 26)0.99
    Neutral

Peers & Related Assets

TYRATyra Biosciences, Inc.
$24.35-4.3%
SVRASavara Inc.
$5.13-2.5%
ABUSArbutus Biopharma Corp
$5.05-0.2%
KURAKura Oncology, Inc.
$11.2-0.9%
SPRYARS Pharmaceuticals, Inc.
$4.17-2.0%
EYPTEyePoint Pharmaceuticals, Inc.
$3.45-5.7%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.